HOPA is an organization that allows hematology/oncology pharmacy practitioners from a variety of practice settings and with a range of experience to share knowledge, learn, interact, and help develop the growing field of clinical hematology/oncology pharmacy. HOPA is a vibrant association, growing each year in membership, benefits and resources, and influence in the healthcare arena. HOPA provides an abundance of learning opportunities. A wide breadth of educational and clinical training programs keep members informed about new drugs and advances in oncology, drug therapies, legislative initiatives, and common challenges and solutions. By participating in HOPA activities, members are granted special access to experienced leaders in the hematology/oncology pharmacy specialty, opening up a world of clinical resources.
The HOPA Board of Directors meets every 6 weeks to discuss strategic initiatives and ensure that the work HOPA does is aligned with the vision and mission of the organization. These summaries aim to make the work of the board of directors and its committees more transparent to HOPA members.
Susannah E. Koontz, PharmD BCOP FHOPA
HOPA President, 2017–2018
The HOPA Board of Directors is pleased to offer a new communication for our members: summaries of highlights of our board meetings. This first installment recaps the day-and-a-half-long retreat we held with the current board of directors, incoming board members, and core members of the HOPA staff in Tampa, FL, at the end of January. In fact, these meeting summaries are a result of one of our retreat topics: making the work of the board and its committees more transparent to HOPA members. I hope this new level of transparency will not only improve communication but also provide some insight on how our volunteer leaders identify, evaluate, and execute strategic initiatives.
At its January retreat, the board of directors first took a close look at HOPA’s mission and vision statements. It is no secret that health care is changing rapidly and moving at the speed of light. As an association, HOPA must be nimble to keep pace with these changes, while remaining loyal to our core mission and vision. Upon close examination of HOPA’s mission statement—Support pharmacy practitioners and promote and advance hematology/oncology pharmacy to optimize the care of individuals affected by cancer—we determined thatit remains relevant and continues to serve as the foundation for our professional development programming, research endeavors, and advocacy activities. Similarly, HOPA’s vision—All individuals affected by cancer have a hematology/oncology pharmacist as an integral member of their care team—continues to be aspirational as we strive for provider status recognition and work to cultivate an increasingly diverse and dynamic pharmacy workforce. We are working to use these professional development opportunities to continue our growth as organizational leaders in providing HOPA the strategic vision to ensure future success.
Next, as we approach the halfway mark of our 2016–2020 strategic plan, the board conducted an assessment of the plan’s utility in enabling us to fulfill our mission and vision. We were pleased to see the significant progress HOPA members together have made in meeting objectives in each of the plan’s four goal areas. Overall, we are further along in our achievements than expected. More details on significant accomplishments during the past year will be shared in March during our Annual Conference in Denver.
Finally, the board also evaluated HOPA’s new committee structure, which was introduced in June 2017. You can expect to see a few adjustments to committee operations in the coming months, including redefining the roles of board liaisons, enhancing the involvement of the councils, ensuring that committee charges are clear and that committee members have adequate guidance from the board, revising the responsibilities of some groups, and fostering communications within and among committees.
Our next board meeting will take place by teleconference on February 21, and I will follow up with a summary shortly thereafter. In the meantime, please feel free to reach out to me with any questions or comments.